Information Provided By:
Fly News Breaks for October 16, 2015
TSRO
Oct 16, 2015 | 06:03 EDT
After speaking to management, Leerink analyst Seamus Fernandez says his confidence in TESARO's strategy for both the Varubi launch for chemotherapy induced nausea and vomiting and the development of niraparib for ovarian cancer remains "extremely high." At $530 per dose, Varubi's initial net price is in line with the analyst's expectation. He maintains an Outperform rating on the stock with a $69 price target.
News For TSRO From the Last 2 Days
There are no results for your query TSRO